Reseach into the effects of sitagliptin on blood sugar control in patients with type2 diabetes

Reseach into the effects of sitagliptin on blood sugar control in patients with type2 diabetes - SPIRITS-J:Sitagliptin Registration Type2 Diabetes-Juntendo Collaborating Project

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004121

Enrollment

3000

Registered

2010-09-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with new onset or poorly controlled type 2 diabetes who are newly or additionally prescribed sitagliptin

Exclusion criteria

Exclusion criteria: 1.Patients sufferd from severe ketosis, diabetic coma or semi-coma within 6-month before participating the study 2.Patients sufferd from severe infection or trauma, and perioperative 3.Possible or definitive pregnant women or nursing mother 4.Serum creatine levels are 1.5mg/dL or more 5.Patients with history of hypersensitivity to any ingredients of sitagliptin tablets 6.Other patients deemed not appropliate for participating to the study by investigators

Design outcomes

Primary

Measure	Time frame
The change of HbA1c levels after prescribing sitagliptin	—

Secondary

Measure	Time frame
the incidence of cardio-, cerebro-vascular events or diabetes-related complications	—

Countries

Japan

Contacts

Public ContactHirotoshi Ohmura

Juntendo University School of Medicine Clinical Research Support Center

juntencrc@juntendo.ac.jp03-3813-3111

Outcome results